GlassScriptPhysician profile
Leslie D Whitney
NPI 1508163593
$15,141.55
in general payments reported to CMS, 2019-2025
37 companies · $3,290 in 2025
The $3,290 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,077 · 2022: $3,311 · 2023: $3,408 · 2024: $3,056 · 2025: $3,290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,753.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,004.96 | 2021-2025 | |
| Aimmune Therapeutics, INC. | $2,227.25 | 2023-2025 | Zenpep, Vowst |
| Nestle Healthcare Nutrition INC. | $1,757.74 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,322.68 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $1,271.76 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $763.63 | 2021-2025 | Entyvio, Eohilia |
| Genzyme Corporation | $729.83 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $534.00 | 2022-2025 | Dupixent |
| Redhill Biopharma INC. | $258.68 | 2021-2023 | Talicia, Aemcolo, Movantik |
| Celgene Corporation | $238.24 | 2023-2024 | Zeposia |
| Madrigal Pharmaceuticals | $215.10 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $153.58 | 2021-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $133.40 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $132.97 | 2023 | Zeposia |
| Boston Scientific Corporation | $131.17 | 2024 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $125.00 | 2023 | |
| Janssen Scientific Affairs, LLC | $114.98 | 2022 | |
| Braintree Laboratories, INC. | $113.57 | 2021-2025 | Suflave, Sutab |
| Intercept Pharmaceuticals, INC. | $112.77 | 2021-2023 | Ocaliva |
| Ferring Pharmaceuticals INC. | $90.12 | 2021-2023 | Rebyota |
| Lilly USA, LLC | $85.99 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $76.19 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $74.59 | 2021-2023 | Linzess |
| Gilead Sciences, INC. | $49.88 | 2022-2024 | |
| Medline Industries LP | $49.22 | 2023-2024 | Medline Industries, INC., Remedy Skin Protectant |
| Fresenius Kabi USA, LLC | $46.20 | 2023-2025 | |
| Phadia US INC. | $42.57 | 2023-2024 | Immunocap |
| Alfasigma USA, INC. | $42.03 | 2021 | |
| Medtronic, INC. | $39.73 | 2023 | Bravo |
| Vivus LLC | $39.52 | 2022-2023 | Qsymia |
| Ardelyx, INC. | $31.32 | 2023 | Ibsrela |
| Novo Nordisk INC | $29.32 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $27.62 | 2022 | |
| Pharmacosmos Therapeutics INC. | $19.67 | 2025 | Monoferric |
| Organon LLC | $19.37 | 2023 | Hadlima |
| W. L. Gore & Associates, INC. | $18.51 | 2022 | |
| Celltrion USA INC. | $18.39 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Whitney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.